---
annotation-target: Genotype_and_Intensive_Pretreatment_Influence.1.pdf
---


>%%
>```annotation-json
>{"created":"2022-08-30T13:22:40.597Z","updated":"2022-08-30T13:22:40.597Z","document":{"title":"Genotype_and_Intensive_Pretreatment_Influence.1.pdf","link":[{"href":"urn:x-pdf:dea843bf3eeef2449e702bbbb1d0ae14"},{"href":"vault:/hematology-theroy/papers/hematology_deeplearning/Genotype_and_Intensive_Pretreatment_Influence.1.pdf"}],"documentFingerprint":"dea843bf3eeef2449e702bbbb1d0ae14"},"uri":"vault:/hematology-theroy/papers/hematology_deeplearning/Genotype_and_Intensive_Pretreatment_Influence.1.pdf","target":[{"source":"vault:/hematology-theroy/papers/hematology_deeplearning/Genotype_and_Intensive_Pretreatment_Influence.1.pdf","selector":[{"type":"TextPositionSelector","start":750,"end":800},{"type":"TextQuoteSelector","exact":"lder than 75 years or unfit for intensive therapy.","prefix":"yeloid leukemia (AML) patients o","suffix":"1,2 Despite the prom-ising  resu"}]}]}
>```
>%%
>*%%PREFIX%%yeloid leukemia (AML) patients o%%HIGHLIGHT%% ==lder than 75 years or unfit for intensive therapy.== %%POSTFIX%%1,2 Despite the prom-ising  resu*
>%%LINK%%[[#^dfd1thyy60p|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^dfd1thyy60p


>%%
>```annotation-json
>{"created":"2022-08-30T13:23:03.690Z","updated":"2022-08-30T13:23:03.690Z","document":{"title":"Genotype_and_Intensive_Pretreatment_Influence.1.pdf","link":[{"href":"urn:x-pdf:dea843bf3eeef2449e702bbbb1d0ae14"},{"href":"vault:/hematology-theroy/papers/hematology_deeplearning/Genotype_and_Intensive_Pretreatment_Influence.1.pdf"}],"documentFingerprint":"dea843bf3eeef2449e702bbbb1d0ae14"},"uri":"vault:/hematology-theroy/papers/hematology_deeplearning/Genotype_and_Intensive_Pretreatment_Influence.1.pdf","target":[{"source":"vault:/hematology-theroy/papers/hematology_deeplearning/Genotype_and_Intensive_Pretreatment_Influence.1.pdf","selector":[{"type":"TextPositionSelector","start":902,"end":1290},{"type":"TextQuoteSelector","exact":"the  identification  of  patients  who  benefit  most  is  still  under  discussion.  Especially  patients  with  IDH1/2  and  NPM1 mutations were reported to benefit from this treatment combination.1–4  In  relapsed/refractory  (r/r)  AML  patients  and  particularly  after  prior  HMA  treatment,  the  impact  on  previ-ous treatment on response is still discussed controversially.5,6","prefix":"ns  as  front-line  treatment,  ","suffix":" As European  Medicines Agency  "}]}]}
>```
>%%
>*%%PREFIX%%ns  as  front-line  treatment,%%HIGHLIGHT%% ==the  identification  of  patients  who  benefit  most  is  still  under  discussion.  Especially  patients  with  IDH1/2  and  NPM1 mutations were reported to benefit from this treatment combination.1–4  In  relapsed/refractory  (r/r)  AML  patients  and  particularly  after  prior  HMA  treatment,  the  impact  on  previ-ous treatment on response is still discussed controversially.5,6== %%POSTFIX%%As European  Medicines Agency*
>%%LINK%%[[#^45u8czvtj4k|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^45u8czvtj4k


>%%
>```annotation-json
>{"created":"2022-08-30T13:25:47.352Z","updated":"2022-08-30T13:25:47.352Z","document":{"title":"Genotype_and_Intensive_Pretreatment_Influence.1.pdf","link":[{"href":"urn:x-pdf:dea843bf3eeef2449e702bbbb1d0ae14"},{"href":"vault:/hematology-theroy/papers/hematology_deeplearning/Genotype_and_Intensive_Pretreatment_Influence.1.pdf"}],"documentFingerprint":"dea843bf3eeef2449e702bbbb1d0ae14"},"uri":"vault:/hematology-theroy/papers/hematology_deeplearning/Genotype_and_Intensive_Pretreatment_Influence.1.pdf","target":[{"source":"vault:/hematology-theroy/papers/hematology_deeplearning/Genotype_and_Intensive_Pretreatment_Influence.1.pdf","selector":[{"type":"TextPositionSelector","start":7650,"end":7736},{"type":"TextQuoteSelector","exact":". ORR was significantly better in patients harboring  NPM1  and/or  IDH1/2  mutations ","prefix":" option in this clinical setting","suffix":" (ORR  87%  vs  33%,  P  <  0.01"}]}]}
>```
>%%
>*%%PREFIX%%option in this clinical setting%%HIGHLIGHT%% ==. ORR was significantly better in patients harboring  NPM1  and/or  IDH1/2  mutations== %%POSTFIX%%(ORR  87%  vs  33%,  P  <  0.01*
>%%LINK%%[[#^9lj6ohwpqxe|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^9lj6ohwpqxe


>%%
>```annotation-json
>{"created":"2022-08-30T13:26:26.839Z","updated":"2022-08-30T13:26:26.839Z","document":{"title":"Genotype_and_Intensive_Pretreatment_Influence.1.pdf","link":[{"href":"urn:x-pdf:dea843bf3eeef2449e702bbbb1d0ae14"},{"href":"vault:/hematology-theroy/papers/hematology_deeplearning/Genotype_and_Intensive_Pretreatment_Influence.1.pdf"}],"documentFingerprint":"dea843bf3eeef2449e702bbbb1d0ae14"},"uri":"vault:/hematology-theroy/papers/hematology_deeplearning/Genotype_and_Intensive_Pretreatment_Influence.1.pdf","target":[{"source":"vault:/hematology-theroy/papers/hematology_deeplearning/Genotype_and_Intensive_Pretreatment_Influence.1.pdf","selector":[{"type":"TextPositionSelector","start":8078,"end":8556},{"type":"TextQuoteSelector","exact":"In  contrast,  age  (≥65  years),  FLT3  mutations,  patients  with  complex  karyotype  or  TP53 mutation as well as prior treatment (allo-HSCT, number of  treatment  lines,  HMA  treatment,  intensive  therapy)  had  no  significant influence on response. The observation that ORR in our study cohort was not influenced by prior HMA treatment is an important finding, as the influence of HMA treatment on response  has  been  discussed  controversially  in  previous  stud-ies","prefix":"  previous  reports.2,3,6,9,10  ","suffix":". DiNardo et al9 and Feld et al6"}]}]}
>```
>%%
>*%%PREFIX%%previous  reports.2,3,6,9,10%%HIGHLIGHT%% ==In  contrast,  age  (≥65  years),  FLT3  mutations,  patients  with  complex  karyotype  or  TP53 mutation as well as prior treatment (allo-HSCT, number of  treatment  lines,  HMA  treatment,  intensive  therapy)  had  no  significant influence on response. The observation that ORR in our study cohort was not influenced by prior HMA treatment is an important finding, as the influence of HMA treatment on response  has  been  discussed  controversially  in  previous  stud-ies== %%POSTFIX%%. DiNardo et al9 and Feld et al6*
>%%LINK%%[[#^upbzssdo6u|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^upbzssdo6u


>%%
>```annotation-json
>{"created":"2022-08-30T13:26:59.698Z","updated":"2022-08-30T13:26:59.698Z","document":{"title":"Genotype_and_Intensive_Pretreatment_Influence.1.pdf","link":[{"href":"urn:x-pdf:dea843bf3eeef2449e702bbbb1d0ae14"},{"href":"vault:/hematology-theroy/papers/hematology_deeplearning/Genotype_and_Intensive_Pretreatment_Influence.1.pdf"}],"documentFingerprint":"dea843bf3eeef2449e702bbbb1d0ae14"},"uri":"vault:/hematology-theroy/papers/hematology_deeplearning/Genotype_and_Intensive_Pretreatment_Influence.1.pdf","target":[{"source":"vault:/hematology-theroy/papers/hematology_deeplearning/Genotype_and_Intensive_Pretreatment_Influence.1.pdf","selector":[{"type":"TextPositionSelector","start":9385,"end":9496},{"type":"TextQuoteSelector","exact":"OS was significantly longer in patients achieving CR/CRi/PR compared with SD/RD patients (P < 0.01; Figure 1A).","prefix":"e entire cohort was 6.5 months. ","suffix":" With respect to prior treatment"}]}]}
>```
>%%
>*%%PREFIX%%e entire cohort was 6.5 months.%%HIGHLIGHT%% ==OS was significantly longer in patients achieving CR/CRi/PR compared with SD/RD patients (P < 0.01; Figure 1A).== %%POSTFIX%%With respect to prior treatment*
>%%LINK%%[[#^h29ua4szggl|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^h29ua4szggl
